The safety data reflect exposure to SPRYCEL in 2,182 patients with leukemia in clinical studies (starting dosage 100 mg once daily, 140 mg once daily, 50 mg twice daily, or 70 mg twice daily).

The FDA has granted full approval for Sprycel (dasatinib tablets, from Bristol-Myers Squibb), an oral tyrosine kinase inhibitor, for the treatment of adults in all phases of chronic myeloid ...

SPRYCEL® (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase July 09, 2010 05:51 PM Eastern Daylight Time ...

DASISION is an open-label, randomized, phase 3 international trial of Sprycel 100 mg tablet taken once-daily (n=259) vs. imatinib 400 mg taken once-daily (n=260) in the treatment of newly-diagnosed CP ...

DASISION (Dasatinib versus Imatinib Study in Treatment-Naïve CP-CML Patients) is an open-label, randomized, Phase 3 international trial of SPRYCEL 100 mg taken once daily vs. imatinib 400 mg ...

Sprycel 50mg Tablet - 60 Tablets (Dasatinib) drug information. Find its price or cost, dose, when to use, how to use, side effects, adverse effects, substitutes .

In 2010, SPRYCEL 100 mg once daily was approved by the FDA and European Commission for the treatment of adult patients with newly diagnosed Ph+ CML in chronic phase. In the U.S., SPRYCEL received ...

Sprycel, Tasigna, and Gleevec battle for supremacy in CML treatment. FDA accepted an sNDA for Bristol-Myers Squibb (BMS) and Otsuka Pharmaceutical’s chronic myeloid leukemia (CML) drug, Sprycel ...

Bristol-Myers Squibb and Otsuka announced that the Food and Drug Administration (FDA) has approved an update to the Sprycel (dasatinib) labeling to include long-term efficacy data.

The safety data reflect exposure to SPRYCEL ® (dasatinib) in 2182 patients with CML or Ph+ ALL in clinical studies with a minimum of 2 years follow-up (starting dosage 100 mg once daily, 140 mg ...